Leading experts have joined together for the first time to call for better screening of psoriatic arthritis to help millions of people suffering from the condition.
Psoriatic arthritis (PsA) causes painful joint inflammation and can cause irreversible joint damage if left untreated.
PsA tends to affect people with the skin condition psoriasis, which causes a red, scaly rash, and affects approximately two per cent of people in the UK. Around one in five go on to develop PsA usually within ten years of the initial skin problem being diagnosed.
Coming together to tackle the gaps in the treatment and diagnosis of psoriatic arthritis, expert rheumatologists, dermatologists and patient representatives from Europe and North America formed the Psoriatic Arthritis Forum, and have now made a series of recommendations to combat the condition.
The recommendations were published in the journal Arthritis Care and Research. They included:
Developing a screening tool for dermatologists and primary care doctors to identify suspected PsA patients
Raising awareness about the progression, health-related quality of life components, and other health issues associated with PsA;
Improving communication between healthcare providers and patients;
Dr Philip Helliwell, of the School of Medicine at the University of Leeds, a member of the Psoriatic Arthritis Forum, said: We believe up to 50% of psoriasis patients with psoriatic arthritis are undiagnosed, living with sore, stiff and tender joints, without understanding what is causing this pain. Our review points the way forward for effective screening and treatment, in the hope that detection rates of the condition are improved and patients enjoy a better quality of life.
In addition to better screening, experts have called for improved referrals of patients, as well as an algorithm a step-by-step procedure for primary care physicians - to be developed to help community physicians on patient evaluation and treatment decisions.
Dr Helliwell added: These recommendations serve as a guide for improving the timely diagnosis of PsA, as well as promoting global awareness of PsA. We need to develop better screening tools as a matter of urgency, as these will be cost-effective and lead to better health outcomes for thousands of people.
This effort was supported in part by the Celgene Corporation.
Dr Philip Helliwell is available for interview. Please contact Ben Jones in the University of Leeds press office on +44 (0)113 343 8059 or email B.P.Jones@leeds.ac.uk.
A factsheet with details of the Forums findings is available.
A copy of the paper published in Arthritis Care and Research is also available.